Clostridium Symbiosum

Most stool tests for colon cancer look for blood. That works best when a tumor or polyp is bleeding. Advanced tumors often do; early ones often do not. This test looks at a different signal: bacterial DNA in stool whose abundance has been reported to rise in people with colorectal polyps or cancer.

In the largest study of it, fecal C. symbiosum rose in steps, from people with benign polyps, to people with cancer still confined to the submucosa, to people with advanced disease. The submucosa is the layer just under the surface lining. That stepwise pattern is what makes the marker interesting. It is also why you should treat this as an early-stage research marker and not a verdict.

What the Test Actually Measures

The result is a stool abundance of this organism's DNA, usually measured by qPCR. qPCR is a lab method that counts copies of a chosen DNA sequence. The number you get back is an abundance, not a yes-or-no infection result.

C. symbiosum is a strict anaerobe. It grows where oxygen is absent, which describes much of the colon. It is not known for toxin production. Because it can stain gram-negative and was once grouped with Fusobacterium-like organisms, older lab methods could confuse it with other gut bacteria. DNA sequencing separates those organisms more cleanly.

Stool DNA sequencing studies link higher levels to a protein-breakdown pattern: more amino acids, creatine, and cadaverine, and less butyrate. Butyrate is a small fat made when gut bacteria ferment fiber. Colon cells use it as fuel. The pattern looks like protein breakdown replacing some of the fiber-fermentation signal. It is still an association.

Colorectal Polyps and Early Cancer

This is where nearly all the human evidence sits. In a multicenter study of 1,037 people, stool levels rose in a clear progression: lowest in controls, higher in people with adenomas, higher still in early cancer, highest in advanced cancer. Adenomas are polyps that can become cancerous.

The most useful finding was in early cancer restricted to the submucosa. That is the stage where five-year survival exceeds 80 percent. C. symbiosum outperformed FIT, blood CEA, and Fusobacterium nucleatum. CEA is a tumor-associated protein measured in serum. That is the stage standard stool-blood tests often miss, because a small early tumor may not be bleeding yet.

On its own it is not enough. When paired with FIT, the model separated early cancer from controls better than FIT alone: 0.803 in the test cohort and 0.707 in validation. On this scale, 0.5 is chance and 1.0 is perfect. Adding CEA and Fusobacterium reached 0.876 for all-stage cancer in the validation cohort.

What this means for you: a high result is a reason to make sure your colorectal screening is current, not a reason to assume you have cancer. This marker was built to work alongside standard screening, and the numbers above come from combinations, not from the bacterium alone.

Why a High Result Does Not Prove Anything Is Growing

Here is the finding that should change how you read your number. In a study of 500 stool samples, blood in stool by itself enriched C. symbiosum, even when colonoscopy found no precancerous or cancerous lesion.

That result cuts both ways. It does not erase the cancer association, because the association held for early submucosal tumors that FIT was missing. But it does mean the number can rise from bleeding alone. A hemorrhoid, a fissure, or any other source of intestinal blood could push it up without a polyp anywhere.

Whether the organism is a passenger or a participant is no longer a settled question. Experimental work published in 2024 reported that C. symbiosum can promote colorectal tumor development in laboratory models, which argues against reading it as a pure bystander. That evidence is preclinical, in cells and animals. It does not establish that the bacterium causes tumors in people, and no study has tested whether lowering it changes any outcome.

An earlier line of animal work on this organism came from germ-free, undernourished mice rather than from colon cancer. In that setting, adding C. symbiosum affected host metabolic signals such as acylcarnitines. Acylcarnitines are molecules involved in fat use.

Liver, Bile Duct, and Inflammatory Bowel Findings

The same organism has appeared in disease signatures outside colon cancer, which limits how specifically you can read a single high number. In one cirrhosis study with 142 people with cirrhosis and 52 controls, C. symbiosum was one of the species associated with cirrhosis-related complications when researchers compared complicated cirrhosis with cirrhosis alone.

It was enriched in a multicenter cholangiocarcinoma stool-DNA study. Cholangiocarcinoma is a bile duct cancer. It has also been reported in ulcerative colitis microbiome signatures with shifted bile acids. The cholangiocarcinoma study then tested its model across 6,847 public samples and found marker overlap with type 2 diabetes, coronary artery disease, and other diseases.

So the same elevated reading fits several different stories. That overlap is the reason this marker cannot stand alone, and the reason your result only becomes meaningful next to the rest of your clinical picture.

Where the Evidence Actually Stands

There are no validated reference ranges or action cutoffs for this stool result. No regulatory body has set a level that separates ordinary carriage from a level that should worry you. The clinical evidence rests largely on one well-conducted cross-sectional study with a validation cohort, supported by stool DNA studies that found the same organism enriched in colorectal cancer across multiple countries.

What does not exist: prospective data following people forward to see whether a high level predicts who develops cancer, follow-up after surgical resection, and any trial showing that changing the number changes an outcome. Current colorectal screening guidelines do not include this bacterium. Routine infectious-diarrhea panels are built for pathogens such as Salmonella, norovirus, and C. difficile, not for this exploratory colorectal-risk organism.

None of that makes the test useless. It makes it exploratory. You are getting a number that has a real published association with colorectal neoplasia and no established threshold for acting on it.

Why One Reading Tells You Little

Gut bacterial abundances move. Daily sampling of healthy adults found that 78 percent of gut bacterial genera vary substantially over time, with stool moisture and recent diet among the biggest drivers. A one-year study of 75 people found that within-person variation explained 23 percent of total variation in gut microbiome composition. A single number from a single day is a snapshot of a moving thing.

That is the case for trending rather than reacting. Get a baseline. If you repeat it, use the same lab, collect on a comparable day, and avoid comparing a loose-stool sample with a formed one. A number that has been steadily climbing across several collections is a different signal from a single high reading.

One caveat on trending: there is no human evidence that any specific diet, probiotic, or treatment moves this particular organism in a predictable direction. Retest to watch the trend, not to check whether an intervention is working. Nobody has shown one does.

What Can Distort a Single Reading

• Blood in the stool: blood inside the gut enriches this organism even with no lesion present. A hemorrhoid, a fissure, or menstrual contamination can push the number up for reasons that have nothing to do with the colon wall.
• Recent antibiotics: antibiotic courses can shift gut bacterial composition for months in some people. Collect before a course or well after it.
• Recent diet and stool consistency: stool moisture and diet were among the strongest drivers of day-to-day variation in quantitative gut profiles. A sample taken during loose stool is not comparable to one taken on a normal day.
• Lab-to-lab differences: single-species qPCR is not standardized across laboratories for this organism. Comparing a result from one lab to a result from another can produce a difference that is entirely technical.

What to Do With an Unexpected Result

Start with the question this test cannot answer: are you current on guideline colorectal screening? If not, that is the action, and no microbiome number should delay it. Colonoscopy and validated stool-based screening tests remain the tools with guideline support, and a stool bacterium does not substitute for them.

If your result is high, the useful companion tests are the ones this marker was studied alongside. FIT tells you whether there is occult blood, which matters twice over here: it addresses the clinical question and flags the main confounder. Fecal calprotectin separates inflammation from everything else. Serum CEA adds information about advanced tumor burden, though it is poor at early disease.

The combinations that warrant fast action are a high bacterial level with a positive occult blood test, or with new changes in bowel habit, unexplained iron deficiency, or visible blood. Those warrant colonoscopy regardless of what the microbiome number says. A high level with a clean occult blood test, no symptoms, and up-to-date screening is usually a reason to retest and watch the trend, not to escalate.

A low or undetectable level is not a deficiency. It reflects ordinary baseline flora and needs no correction.